Last Updated : June 28, 2024
Details
FilesGeneric Name:
lecanemab
Project Status:
Active
Therapeutic Area:
Alzheimer’s disease
Manufacturer:
Eisai Canada
Call for patient/clinician input open:
Brand Name:
Leqembi
Project Line:
Reimbursement Review
Project Number:
SR0822-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Lecanemab is a
disease-modifying treatment for adult patients with Alzheimer’s disease.
Treatment with lecanemab should be initiated in patients with mild cognitive
impairment or mild dementia stage of disease. Patients must have documented
presence of amyloid beta pathology. Lecanemab should be prescribed by
clinicians with expertise in diagnosing, managing and treating patients with mild cognitive
impairment or mild dementia stage of disease (early AD).
Submission Type:
Initial
Fee Schedule:
Schedule E
Indications:
Lecanemab is indicated as a disease-modifying
treatment in adult patients with Alzheimer’s disease. Treatment with lecanemab
should be initiated in patients with mild cognitive impairment or mild dementia
stage of disease.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | April 25, 2024 |
|---|---|
| Call for patient/clinician input closed | June 17, 2024 |
| Submission received | June 14, 2024 |
| Submission accepted | June 28, 2024 |
| Review initiated | July 02, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | October 15, 2024 |
| Deadline for sponsors comments | October 24, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | December 06, 2024 |
| Expert committee meeting (initial) | December 18, 2024 |
| Draft recommendation issued to sponsor | January 07, 2025 To January 09, 2025 |
| Draft recommendation posted for stakeholder feedback | January 16, 2025 |
| End of feedback period | January 31, 2025 |
Files
Last Updated : June 28, 2024